ReviewDrug design, development and therapy2021
Chronic Obstructive Pulmonary Disease Treatment and Pharmacist-Led Medication Management.
Review in Drug design, development and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Management of COPD and comorbidities in COPD patients by dispensing pharmaceutical care following Global Initiative for Chronic Obstructive Lung Disease-guidelines (GOLD guidelines 2020): a prospective randomized clinical trial.BMC health services research · 2026Trial
- Trial
- Credentialed pharmacist-led home medicines reviews targeting treatable traits and their impact on health outcomes in people with chronic obstructive pulmonary disease: a pre- and post-intervention study.International journal of clinical pharmacy · 2025Trial
- Recurrent urticaria induced by aspirin in a post-stent patient: A case study and literature review.The Journal of international medical research · 2026Review
- Commentary: Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data.Frontiers in medicine · 2026Article
- Voriconazole pseudotoxicity: a case report highlighting the importance of sampling timing in TDM interpretation by clinical pharmacists.Frontiers in medicine · 2026Article
- Modulation of Inflammatory and Oxidative Stress Pathways in COPD: Unraveling the Mechanisms of Fenugreek Through Network Pharmacology and Single-Cell RNA Sequencing.International journal of chronic obstructive pulmonary disease · 2026Article
- A bibliometric review of triazine hybrids: synthesis, reactions, and applications spanning the last quarter-century (2000-2025).RSC advances · 2025Review
- Care pathways versus usual care for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2024Article
- Transforming respiratory diseases management: a CMO-based hospital pharmaceutical care model.Frontiers in pharmacology · 2024Article
- Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease.Journal of microbiology and biotechnology · 2023Review
- Bufei Yishen Formula Inhibits the Cell Senescence in COPD by Up-Regulating the ZNF263 and Klotho Expression.International journal of chronic obstructive pulmonary disease · 2023Article
- A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines.AAPS PharmSciTech · 2022Review
- Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a.International journal of biological sciences · 2022Article
- Efficacy and potential mechanisms of Chinese herbal compounds in coronavirus disease 2019: advances of laboratory and clinical studies.Chinese medicine · 2021Review
- Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review.Integrative medicine research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death across the globe. Its repeated exacerbation will seriously worsen the quality of life, aggravate the patients' symptoms, and bring a heavy burden on the patients and the society. Understanding the current status of drug therapy and the role of pharmaceutical care is essential for the management of COPD. In addition to the drugs already on the market, recent clinical trials also show that emerging novel drugs for treating COPD are being developed to prevent the symptoms, reduce the frequency of acute exacerbation, and improve the quality of life. Recent progress in new drug research should lead to novel treatment options for COPD patients in future clinical practice. The pharmaceutical care has shown significantly favourable impacts on addressing drug-related problems, supporting its vital role in the management of COPD, especially when there are a wide range of therapeutic agents. This review not only provides an overview of current treatment strategies but also further underlines the importance of new drug development and pharmaceutical care for patients with COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.